Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?
Yükleniyor...
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Tubitak Scientific & Technical Research Council
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Abstract: To combat the coronaviruses and their novel variants, therapeutic drugs and the development of vaccines that are to be
effective throughout human life are urgently needed. The endocannabinoid system (ECS) acts as a modulator in the activation of the
microcirculation, immune system, and autonomic nervous system, along with controlling pharmacological functions such as emotional
responses, homeostasis, motor functions, cognition, and motivation. The ECS contains endogenous cannabinoids, cannabinoid
receptor (CBRs), and enzymes that regulate their biosynthesis, transport, and degradation. Moreover, phytocannabinoids and synthetic
cannabinoids that mimic the action of endocannabinoids also play an essential role in the modulation of the ECS. Cannabinoids, the
main constituents of cannabis (Cannabis sativa L.), are therapeutic compounds that have received international attention in the health
field due to their therapeutic properties. Recently, they have been tested for the treatment of COVID-19 due to their antiviral properties.
Indeed, cannabinoid-type compounds, and in particular cannabidiol (CBD), isolated from glandular trichomes found in the calyx
of cannabis flowers with reported antiviral properties is hypothesized to be a therapeutic option in the ministration of SARS-CoV-2
consorted with COVID-19 disease. The relevant articles were determined from the database search published mainly in Web of Science,
Google scholar, PubMed, Crossref, and ClinicalTrials.gov database during the pandemic period. The articles were evaluated for the
therapeutic potentials, mechanisms of action of cannabinoids, the roles of the ECS in the immune system, impact of cannabinoids in
SARS-CoV-2 septic, especially if they address the application of cannabinoids as drugs for the curability and management of SARSCoV-2 and its novel variants. Although the evidence needed to be considered using cannabinoids in the control and treatment of viral
diseases is currently in its infancy, they already offer an opportunity for clinicians due to their effects in relieving pain, improving
appetite, and improving childhood epilepsy, especially in cancer and human immunodeficiency virus (HIV/AIDS) patients. In addition
to these, the most recent scientific evidence emphasizes their use in the treatment of the coronavirus infected patients. In brief, all
preclinic and clinic studies that have been reported show that, through the cannabinoid system, cannabinoids, particularly CBD, have
many mechanisms that are effective in the treatment of patients infected by SARS-CoV-2. Thus, more extensive studies are necessary in
this area to fully identify the effects of cannabinoids on SARS-CoV-2.
Açıklama
WOS:000691376800017
Anahtar Kelimeler
Antiviral, Cannabidiol, Cannabinoids, Cannabinoid system, COVID-19, SARS-CoV-2
Kaynak
Turkish Journal of Biology
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
5
Sayı
4 SI
Künye
Onay, A., Ertaş, A., Süzerer, V., Yener, İ., Yılmaz, M.A., Ayaz-Tilkat, E. ve diğerleri. Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy? Turkish Journal of Biology, 5(4), 570-587. (Special Issue SI)
